Interferon Reduces Recurrences of Basal Cell and Squamous Cell Cancers

Ikíc, D.; Padovan, I; Pipić, Nedim; Čajkovac, Vladimir; Kusić, Zvonko; Đaković, Nikola; Gregurek‐Novak, Teodora; Soldo-Belić, Antica; Spaventi, Šime; Belicza, Mladen; Ferenčić, Željko

doi:10.1111/j.1365-4362.1995.tb04382.x

Cited by 24 publications

(12 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Kuflik et al 16 reported a 5-year cure rate of 96% for SCC achieved by cryosurgery. Ikic et al 17 demonstrated that the interferon treatment can produce a persistent cure (5 years) in patients with SCC (recurrence rate, 4%). A complete response rate of 63% was achieved with topical PDT in superficial SCC on face, scalp, or neck.…”

Section: Discussionmentioning

confidence: 97%

Clearance of a Thick Invasive Squamous Cell Carcinoma After Multiple Treatments with Topical Photodynamic Therapy

Gao

Long

et al. 2010

Photomedicine and Laser Surgery

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Clearance of a Thick Invasive Squamous Cell Carcinoma After Multiple Treatments with Topical Photodynamic Therapy

Gao

Long

et al. 2010

Photomedicine and Laser Surgery

View full text Add to dashboard Cite

show abstract

“…Some preliminary evidence suggests that vitamin supplementation may reduce the risk of basal cell carcinoma28 and that interferon reduces recurrence. 29 Further studies are required to confirm these observations. The choice of treatment depends on the size and site of tumour, age of patient, efficacy of treatment modality, cosmetic considerations, and the preferences of patient and physician.…”

Section: Predisposing Factorsmentioning

confidence: 96%

Basal cell carcinoma

Lear

Smith

1997

Postgraduate Medical Journal

View full text Add to dashboard Cite

Summary Basal cell carcinoma is the commonest malignancy in Caucasians with incidence rates of 300 per 100,000 reported in the USA. Rates are increasing at over 10% per year leading to a lifetime risk of 30%. Although mortality is low, the disease is responsible for considerable morbidity and places a substantial burden on health service provision in the UK. Furthermore, lesions may recur and patients often develop multiple tumours giving major implications for treatment and follow-up. Four main types of basal cell carcinoma are seen: nodulo-ulcerative; pigmented; morpheaform and superficial. Diagnosis is by histological evaluation although many tumours have a characteristic clinical appearance. The differential diagnosis is large. Identified risk factors include male gender, skin type 1, red/blonde hair and increasing age. Patients with basal cell carcinoma are more likely to develop malignant melanoma and squamous cell carcinoma but it is still unclear whether there is a link with internal malignancy. The main treatment modalities are surgery and radiotherapy. Each has advantages and disadvantages. The choice of treatment depends on many factors. Principles of treatment include identification of high-risk patients to enable early detection, complete removal of the lesion, and careful follow-up to detect recurrence or new lesions. Approximately 10% of tumours recur, depending on site, size and treatment modality. Metastatic basal cell carcinoma and the association of ultraviolet radiation to basal cell carcinoma risk are reviewed.

show abstract

“…Kuflik and Gage 10 reported a 5-year cure rate of 99% for BCC and 96% for SCC achieved by cryosurgery. Ikic et al 20 demonstrated that interferon treatment can produce a persistent cure (5 years) in patients with *The lesions were treated with different wave bands of light, including fullspectrum visible light, filtered visible light ( Ͼ515, Ͼ570, or Ͼ610 nm), and UV-A, as specified in the "Patients, Materials, and Methods" section. There was no statistically significant difference among the clinical response rates of basal cell carcinoma and squamous cell carcinoma to the different wave bands of light.…”

Section: Commentmentioning

confidence: 99%

Long-term Follow-up and Histological Changes of Superficial Nonmelanoma Skin Cancers Treated With Topical δ-Aminolevulinic Acid Photodynamic Therapy

Fink‐Puches¹,

Soyer²,

Hofer³

et al. 1998

Arch Dermatol

145

101

View full text Add to dashboard Cite

To investigate the immediate and longterm effects of photodynamic therapy with ␦-aminolevulinic acid (ALA-PDT) on superficial basal cell carcinomas (BCC) and superficial squamous cell carcinomas (SCC).Design: Retrospective study with 60 months of maximal follow-up.Setting: University-based hospital in Graz, Austria.Patients: Forty-seven subjects with a total of 95 superficial BCC and 35 superficial SCC.Interventions: A compound of 20% ␦-aminolevulinic acid was topically applied under an occlusive and lightshielding dressing before exposure to either UV-A or different wave bands of polychromatic visible light (fullspectrum visible light, Ͼ515, Ͼ570, or Ͼ610 nm).Main Outcome Measures: Primary tumor responses and recurrence rates in the long-term follow-up, as well as histological changes associated with ALA-PDT, were studied.Results: The complete primary response rate for all wave bands of light was 86% (82/95) for superficial BCC and 54% (19/35) for superficial SCC. There was no statisti-cally significant difference among the response rates to the different wave bands of light. After a median follow-up of 19 months (range, 3-60 months) for BCC and 8 months (range, 3-47 months) for SCC, the overall recurrence rate was 44% (36/81) and 69% (11/16), respectively. At 36 months after therapy, the projected disease-free rate was 50% (95% confidence interval, 43%-57%) for BCC vs 8% (95% confidence interval, 7%-9%) for SCC (PϽ.001, log-rank test). Histopathologic studies revealed a significant increase of fibrosis in the dermis after ALA-PDT and appearance of a sharp border between fibrotic and nonfibrotic tissue. In 15 of 16 BCC examined, the border between fibrotic and nonfibrotic tissue was deeper in the dermis than the maximum tumor thickness before therapy (PϽ.001, Wilcoxon signed rank test). Similar histopathologic observations were made in SCC. Conclusions:Our study revealed poor long-term cure rates for superficial BCC and SCC treated with topical ALA-PDT and visible light. The histopathologic observations showing remarkable fibrosis in the dermis indicated that the effect of ALA-PDT reached deeper than the initial depth of invasiveness of the neoplastic tissue, suggesting in turn that the poor long-term results of ALA-PDT cannot be explained by insufficient penetration of the therapy effect.

show abstract

Interferon Reduces Recurrences of Basal Cell and Squamous Cell Cancers

Abstract: Interferon treatment makes it possible to achieve a persistent cure in patients with BCC and SCC in a high proportion of cases. The potential advantage of nonsurgical treatment are an enhancement of cosmetic results through the prevention of destruction of important anatomic structures.

Cited by 24 publications

References 9 publications

Clearance of a Thick Invasive Squamous Cell Carcinoma After Multiple Treatments with Topical Photodynamic Therapy

Clearance of a Thick Invasive Squamous Cell Carcinoma After Multiple Treatments with Topical Photodynamic Therapy

Basal cell carcinoma

Long-term Follow-up and Histological Changes of Superficial Nonmelanoma Skin Cancers Treated With Topical δ-Aminolevulinic Acid Photodynamic Therapy

Contact Info

Product

Resources

About